Which regulatory submission does 21 CFR 314 primarily address?

21 CFR 314 is primarily focused on the regulations governing the approval process for new drug applications (NDAs) submitted to the FDA. This part of the Code of Federal Regulations outlines the requirements and procedures that applicants must follow to obtain approval for marketing a new drug. It encompasses critical aspects such as the formulation of the NDA, the data needed to support safety and efficacy, labeling requirements, and the manufacturing information necessary for the drug.

The emphasis on applications for FDA approval to market a new drug captures the regulatory framework that must be adhered to when seeking official authorization to sell a new pharmaceutical product in the United States. Understanding this part of the regulations is essential for anyone involved in drug development, as compliance with these guidelines is required for successful submission and eventual product launch.